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Abstract: Activation of the renin–angiotensin system (RAS) is signiﬁ  cant in the pathogenesis 
of cardiovascular disease and speciﬁ  cally coronary atherosclerosis. There is strong evidence 
that the RAS has effects on the mechanisms of action of atherosclerosis, including ﬁ  brinolytic 
balance, endothelial function, and plaque stability. Pharmacological inhibition of the renin 
angiotensin system includes angiotensin converting enzyme (ACE) inhibitors, angiotensin 
receptor blockers (ARBs), and renin inhibitors. These agents have clinical beneﬁ  ts in reducing 
morbidity and mortality in the management of hypertension. In addition, ACE inhibitors and 
ARBs have shown to be effective in the management of congestive heart failure and acute 
myocardial infarction. This review article discusses the biochemical and molecular mechanisms 
involving the RAS in coronary atherosclerosis as well as the effects of RAS inhibition in clinical 
studies involving coronary atherosclerosis.
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Introduction
Since the initial elucidation of angiotensin II (angII) over ﬁ  fty years ago, it has become 
evident that the renin–angiotensin system (RAS) plays a pivotal role in normal hemo-
dynamics and regulation of volume status. Furthermore, activation of the RAS is 
signiﬁ  cant in the pathogenesis of cardiovascular processes. Initial studies have focused 
on the importance of RAS blockade in left ventricular dysfunction. However, there 
is an effect of the RAS on progression of coronary atherosclerosis through its inﬂ  u-
ence on ﬁ  brinolytic balance, vascular endothelial function, inﬂ  ammation and plaque 
instability (Tsikouris and Cox 2003; Kon and Jabs 2004).
ACE inhibitors and angiotensin receptor blockers (ARBs) and more recently direct 
renin inhibitors are agents used to block the effects of the RAS. While they have been 
used effectively in hypertension and renal disease (Kon and Jabs 2004), their effects 
on reducing the morbidity and mortality associated with heart failure and myocardial 
infarction have triggered extensive research into the beneﬁ  ts of these agents beyond 
blood pressure reduction (The SOLVD Investigators 1991, 1992; Pfeffer et al 1992). 
Three large trials have assessed the efﬁ  cacy of ACE inhibitors in stable coronary 
disease with conﬂ  icting results (HOPE 2000; Fox et al 2003; PEACE 2004). There 
are ongoing trials of ARBs in this patient population. Furthermore, the recent release 
of direct renin inhibitors potentially may add even more information to the association 
of RAS and coronary atherosclerosis.
In this review, we will examine the evidence for beneﬁ  t of RAS blockade in the 
secondary prevention of coronary atherosclerosis. Furthermore, there is increasing 
evidence of the importance of these agents in metabolic syndrome and insulin resis-
tance, a growing risk factor for the development of cardiovascular disease. Thus, we Vascular Health and Risk Management 2007:3(6) 938
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will also examine the potential role of these agents prior to 
the overt development of coronary atherosclerosis.
Metabolic effects of the renin–
angiotensin system
The importance of lipid and glucose metabolism in the patho-
genesis of atherosclerosis is increasingly evident. Metabolic 
syndrome is a constellation of atherogenic risk factors includ-
ing hypertension, dyslipidemia, and hyperglycemia that are 
associated with a pro-inﬂ  ammatory and pro-thrombotic 
milieu. Deﬁ  nitions of this disorder have been controversial, 
but the most recent NCEP/ATPIII guidelines provide a list 
of criteria that have been the most widely accepted. Based on 
these deﬁ  nitions, the approximate prevalence of metabolic 
syndrome in the United States adult population may be as 
high as 25% (Prasad and Quyyumi 2004). The magnitude 
of this problem is ampliﬁ  ed when we consider the potential 
risk this disease imposes on an individual. Estimates indicate 
that the metabolic syndrome increases the risk of stroke two 
to four fold and myocardial infarction three to four fold in 
comparison to general population (Lakka et al 2002).
The hallmark of the metabolic syndrome appears to 
be hyperinsulinemia and insulin resistance (Prasad and 
Quyyumi 2004). Insulin has been shown to have vasodilatory 
and anti-inﬂ  ammatory effects (Cusi et al 2000; Montagnani 
et al 2002). Therefore, with the development of insulin resis-
tance, the balance of these effects may be skewed to favor 
the development of atherosclerosis. Considerable evidence 
suggests that Ang II may modulate the action of insulin 
through inhibition of the phosphatidyl inositol pathway 
(PI3) and stimulation of the MAP kinase pathway (Velloso 
et al 1996). Likewise, both hyperglycemia and insulin acti-
vate the RAS by increasing expression of angiotensinogen, 
Ang II, and regulation and activity of the angiotensin type 1 
(AT1) receptor. In addition, insulin resistance is associated 
with increased NADPH oxidase (Rajagopalan et al 1996; 
Griendling et al 2000) and reactive oxygen species, another 
potential mechanism of vascular injury in these patients 
(Schmidt et al 1999). Another potential cause of reduced 
insulin sensitivity through RAS activation may be a result 
of vasoconstrictive effects, thereby reducing blood ﬂ  ow to 
skeletal muscle (Furuhashi et al 2003).
This interaction between the RAS and glucose metabo-
lism has been further supported by analyzing the effects of 
RAS blockade on enhanced insulin sensitivity. It has been 
suggested that ACE inhibitors improve glycemic control 
in diabetic patients (Pollare et al 1989). This is evidenced 
through clinical studies showing the reduction in progression 
to overt diabetes mellitus. In the CAPPP study, captopril was 
found to reduce the incidence of type II diabetes mellitus 
(DM) by 14% (Hansson et al 1999). In addition, these ﬁ  nd-
ings were reproduced in the HOPE trial, which found a 34% 
reduction in new onset DM and a 16% reduction in compli-
cations from DM in patients treated with ramipril (HOPE 
2000; Yusuf et al 2001).
Similar ﬁ  ndings were also found in the PEACE trial, 
despite lack of efﬁ  cacy in the primary outcome, when patients 
were treated with trandolapril (PEACE 2004). Additionally, 
in the SECURE trial, a substudy of the HOPE study, ramipril 
appeared to decrease fasting glucose levels in comparison to 
placebo (Lonn et al 2000). The improved insulin sensitivity 
seen with ACE inhibitors appears to results in an increased 
glucose uptake by skeletal muscles via enhanced synthesis and 
translocation of the glucose transporter 4 protein to the cell 
surface. This effect is facilitated by up-regulation of tyrosine 
phosphorylation of IRS-1 (insulin receptor substrate) and 
enhanced bradykinin and NO activity (Krutzfeldt et al 2000; 
Shiuchi et al 2002). The effect of RAS blockade via ARBs 
also has signiﬁ  cant effects on glucose metabolism. In the LIFE 
study, a 25% reduction of new onset DM was seen in patients 
treated with losartan in comparison to atenolol (Dahlöf et al 
2002; Lindholm et al 2002). In addition, the VALUE study 
has shown similar ﬁ  ndings in patients treated with valsartan 
in comparison to amlodipine (Julius et al 2003).
A logical question raised by this clinical data is whether 
RAS blockade would be an appropriate treatment for 
patients with metabolic syndrome. It is conceivable that 
RAS blockade would not only prevent the progression to 
overt DM but would also ameliorate the documented risk 
of atherosclerosis in these patients. In experimental animal 
models, this hypothesis has been supported. In a study of 
mice with the metabolic syndrome, treatment with ARBs 
inhibited development of hyperinsulinemia, HTN, obesity, 
cardiac hypertrophy and atherosclerosis (Ortlepp et al 
2002). While the clinical data in this ﬁ  eld is limited, there 
is potential beneﬁ  t of RAS blockade suggested through sur-
rogate markers. Adiponectin is a adipocyte derived protein 
that has been found to have an important correlation to not 
only obesity, but coronary atherosclerosis. Adiponectin is 
believed to enhance insulin sensitivity, preserve endothelial 
function, reduce vascular smooth muscle proliferation and 
suppress macrophage foam cell formation (Lau et al 2005). 
It is thought that reduced circulating levels of this protein 
are associated with an increased risk of coronary artery 
disease (Pischon et al 2004). In this study, it was observed Vascular Health and Risk Management 2007:3(6) 939
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that treatment with either temocapril or candesartan resulted 
in signiﬁ  cant increases in adiponectin levels (Furuhashi 
et al 2003). In a small, clinical study (Nagamia et al 2007), 
treatment with quinapril in comparison to placebo resulted 
in an increase in adiponectin, decrease in serum leptins and 
positive improvement on insulin sensitivity.
The largest trial to date looking speciﬁ  cally at the effects 
of RAS blockade on insulin sensitivity was recently released. 
The DREAM trial randomized 5269 patients, with no cardio-
vascular disease but either impaired fasting glucose levels 
or impaired glucose tolerance, to either ramipril or placebo 
for a period of three years. Although there was no signiﬁ  cant 
decrease in the primary outcome of death or new onset diabe-
tes, patients on ramipril were likely to regress to normogly-
cemia and had improved glucose tolerance (DREAM 2006). 
We are currently awaiting the results of the Nateglinide and 
Valsartan in Impaired Glucose Tolerance Outcomes Research 
(NAVIGATOR) which will be the largest randomized trial to 
date evaluating diabetes prevention. This study will compare 
the cardiovascular effects of valsartan and nateglinide, an 
oral hypoglycemic, in a population of patients with impaired 
glucose tolerance. While the primary outcome of this study 
will be a composite endpoint of cardiovascular events, there 
will also be an important secondary outcome of progression 
to diabetes mellitus (Prasad and Quyyumi 2004). The study 
is scheduled to be completed in 2007 and will provide useful 
information regarding inhibition of RAS with ARBs in 
patients with glucose intolerance and metabolic syndrome.
In summary, DM and metabolic syndrome are important 
cardiovascular risk factors that seem to have important links 
to the RAS. Perturbations of this abnormality in lipid and 
glucose metabolism can be achieved with blockade of the 
RAS system and may be a potential mechanism for their 
beneﬁ  t in coronary atherosclerosis.
Clinical trials of ACE inhibitors 
in stable coronary artery disease
ACE inhibitors have now been deﬁ  nitively shown to reduce 
mortality and morbidity in patients with systolic heart fail-
ure, myocardial infarction (with or without left ventricular 
dysfunction), and those undergoing percutaneous coronary 
intervention (Al-Mallah et al 2006). In addition to their 
well-established role in the treatment of hypertension, ACE 
inhibitors also help to decrease cardiovascular events in 
patients with diabetes mellitus and renal dysfunction. How-
ever, controversy persists as to whether these agents are 
beneﬁ  cial or not in patients with stable CAD and preserved 
left ventricular function.
Three large clinical trials have been performed to date 
that attempted to address this issue: HOPE, PEACE and 
EUROPA. We provide a comparison of the important 
aspects of these trials in Table 1. The HOPE trial enrolled 
9297 patients with history of stroke, coronary atheroscle-
rosis, peripheral vascular disease or DM plus at least one 
other cardiovascular risk factor, such as hypertension, dys-
lipidemia, smoking or documented microalbuminuria and 
excluded patients with systolic ventricular dysfunction. Over 
a 4.5 year period of follow-up, patients treated with ramipril 
(10 mg/day) were found to have a 22% relative reduction in 
the primary outcome of myocardial infarction, cardiovascular 
death and stroke compared to placebo (HOPE 2000). In addi-
tion, there was a signiﬁ  cant decrease in secondary outcomes 
of revascularization, cardiac arrest, CHF, complications and 
diagnosis of new onset type II diabetes mellitus (as mentioned 
previously). This landmark trial seemingly advocated for the 
use of ACE inhibitors in all high risk patients with athero-
sclerosis and/or DM.
This study was followed by an even larger study, the 
EUROPA trial, which randomized 12218 patients with evi-
dence of coronary artery disease but no systolic dysfunction 
to either perindopril 8 mg or placebo for a mean follow up 
of 4.2 years. In this study, there was a 20% reduction in the 
composite primary end point of cardiovascular event (Fox 
et al 2003). While the HOPE and EUROPA studies seemed 
to suggest the efﬁ  cacy of ACE inhibitors in the secondary pre-
vention of coronary disease, controversy was created with the 
release of the PEACE trial. This large-scale study randomized 
8290 patients with coronary atherosclerosis and preserved 
ventricular function to either trandolapril 4 mg or placebo for a 
mean follow up of 4.8 years (PEACE 2004). However, unlike 
the HOPE and EUROPA trials, this trial found no statistical 
difference on the same composite end point used in the other 
trials (CV death, MI or revascularization).
In trying to hypothesize the mechanisms for these con-
ﬂ  icting results, it is necessary to analyze the characteristics 
of each study (see Table 1). The main differences that could 
explain this discrepancy are the relative cardiovascular risk 
of each population, differences in mean blood pressure 
control and differences in ACE inhibitor dosing. The popu-
lation in the HOPE study was a group of high risk patients 
with stringent inclusion criteria. Hence, this was an older 
population with signiﬁ  cantly more cardiovascular risk based 
on traditional Framingham risk factors. This potentially 
explains the increase in revascularization needed when 
compared to the EUROPA and PEACE studies. In addition, 
if we compare PEACE and EUROPA, the former had a 72% Vascular Health and Risk Management 2007:3(6) 940
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revascularization rate versus 55% in EUROPA and 40% in 
HOPE prior to enrollment in the study. Thus, this is a poten-
tially important marker of patients whose coronary disease 
was not optimally treated. Looking through these three trials, 
it becomes evident that the PEACE population had the lowest 
cardiovascular risk. Since patients were more likely to be 
on optimum medical therapy in the PEACE trial, the study 
raised the important question of whether there is a level of 
risk at which there is beneﬁ  t of ACE inhibition.
Another intriguing difference between these studies was 
the mean blood pressure of patients treated in each study. In 
the PEACE trial, mean BP was somewhat lower at 133/78 
mmHg compared to EUROPA at 137/82 mmHg and HOPE 
at 139/79 mmHg. While this modest difference between 
blood pressures may seem to be trivial, one must consider 
the reduction of blood pressure that has been shown to reduce 
cardiovascular events (Collins et al 1990). With this in mind, 
these small differences in blood pressure may at least partially 
explain the negative results of the PEACE trial.
Another potential explanation for the negative results 
of the PEACE trial has been the relatively low dosing of 
trandolapril used in the study. The trandolapril dose used 
in PEACE was based on dosing used in both the TRACE 
trial, the initial trial showing beneﬁ  t of this agent after MI in 
patients with left ventricular dysfunction (Køber et al 1995) 
and the initial dosing studies showing the dose needed to 
decrease blood pressure in subjects with hypertension (Guay 
2003). Despite the seemingly valid rationale for the trandol-
april dosing, some critics have hypothesized that patients with 
stable coronary disease and preserved left ventricular func-
tion may need higher doses of ACE inhibitor than those with 
left ventricular dysfunction, as the latter group has increased 
secretion of growth factors, cytokines, signaling pathways 
and neurohormones (Pitt 2004). Additionally, while there has 
been concern about differences in different pharmacokinetics 
of ACE inhibitors, tissue versus non-tissue speciﬁ  c, it should 
be noted that all of the ACE-inhibitors used in these three 
trials were considered to be tissue-speciﬁ  c (Cushman et al 
1989; Miyazaki et al 1995; Pitt et al 2001).
Given the potential of the differing medical therapies in 
these three studies, there has been some interest in further 
evaluating the interaction of RAS blockade and lipid lower-
ing therapy. In the TREND study, 125 normotensive patients 
with stable coronary artery disease and LDL  165 mg/dl 
Table 1 Comparison of several major clinical trials of the effect of ACEI on pertinent cardiovascular events, onset of diabetes, inﬂ  am-
matory markers and ﬂ  ow mediated dilatation (FMD)
 HOPE  EUROPA  PEACE  LIFE  DREAM  Khan1
No. of patients  9297  12218  8290  9193  5269  112
Mean follow up (yrs)  4.5  4.2  4.8  4.8  3*  24 weeks
Primary end point  CV death,  CV death,  CV death, MI,  CV  Onset of  Inﬂ  ammatory
  MI, stroke  MI, cardiac  revascularization  death,  diabetes  markers
    arrest    stroke, MI  or death
Reduction in  22  20  None  13  None  44% decrease for
cardiovascular          IL-6;  53%–56%
events (%)            decrease for CD11bR
Reduction in new  34  None  15  25  None  NR
onset diabetes (%)
Treatment Ramipril  Perindopril  Trandolapril  Losartan  Ramipril  Quinapril,  Irbesartan
Mean age (yrs)  66 ± 7  60 ± 9  64 ± 8  67 ± 7  55 ± 11  60 ± 9
Females  (%)  25  15  18  54 59 43
HTN (%)  47  27  46  100  44  47
Mean  BP  139/79  137/82  133/78  174/98 136/83 131/NR
SBP/DBP 3/2  5/2  3/1  30/17  8/4  3/NR
lowering (mmHg)
Revascularization  (%)  40  54  72  NR NR 100
Diabetes (%)  38  12  17  13  9**  NR
Lipid lowering  29  58  70  NR  15  100
medications (%)
Aspirin or other  76  92  90  NR  14  100
antiplatelets (%)
BB (%)  40  62  60  NR  18  70
Notes: 1Lauten et al 2003; *  The DREAM trial reported median years of follow-up; **Previous gestational diabetes considered without overt diabetes at time of study 
enrollment.
Abbreviations: CV, cardiovascular; MI, myocardial infarction; NR, not reported in study; SBP, systolic blood pressure; DBP, diastolic blood pressure.Vascular Health and Risk Management 2007:3(6) 941
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were randomized to quinapril or placebo for 6 months. 
Compared to placebo, patients treated with quinapril showed 
an improvement in endothelial function tested by coronary 
vasodilatory response to intracoronary infusion of acetyl-
choline. However, the beneﬁ  t on endothelial function was 
only signiﬁ  cant in those with an LDL  125 mg/dl (Mancini 
et al 1996). The proposed reasoning behind this ﬁ  nding 
as been that ACE inhibitors share a common mechanism 
with statins on lectin–like oxidized LDL receptors and thus 
reduce oxidation of LDL cholesterol (Szmitko et al 2003). 
In another study, 112 patients with coronary atherosclerosis 
were initiated on atorvastatin for an average of 3.7 months 
to reach a target LDL  100 mg/dL, then randomized to 
quinapril (20 mg/day), irbesartan (150 mg/day) or placebo for 
a period of 24 weeks. In patients treated with quinapril and 
irbesartan, but not placebo, there was a signiﬁ  cant reduction 
in soluble interleukin-6 (sIL-6) and CD11b receptor (Lauten 
et al 2003). A recent study on patients with the metabolic 
syndrome treated with quinapril versus placebo for 4 weeks 
showed a signiﬁ  cant reduction in the lag time to oxidation of 
LDL in the quinapril group (Khan et al 2004). It should be 
noted that the average LDL level in this study was 125 mg/dL. 
Another possibility is that statins could dampen the effects 
of RAS blockade through their known anti-inﬂ  ammatory 
effect (Al-Mallah et al 2006) and inhibition of the formation 
of reactive oxygen species (Griendling et al 1994; Wagner 
et al 2000). Thus, as was seen in the PEACE trial, it seems 
plausible that lower levels of LDL from increased use of 
lipid lowering agents may negate the beneﬁ  cial effect from 
ACE inhibitor treatment on atherosclerosis.
Another smaller study on ACE inhibition in stable 
coronary disease that had negative results was the QUIET 
trial (Pitt et al 2001). In this study, 1750 patients with docu-
mented CAD by angiography and LDL  165 mg/dL were 
randomized to 20 mg of quinapril or placebo for a period of 
27.0 ± 0.3 months. While they did not ﬁ  nd patients treated 
with quinapril had a signiﬁ  cant reduction in ischemic events, 
they did show a signiﬁ  cant decrease in angioplasty for new 
previously unintervened vessels. Thus, despite some limita-
tions to this study, including the lower dose of ACE inhibitor 
used than in the TREND trial (Mancini et al 1996), shorter 
duration of therapy, much lower mean blood pressure and 
inadequate power, there was still objective evidence of 
slowed progression of atherosclerosis in patients treated 
with ACE inhibitors.
Important clinical information on RAS blockade can 
also be extracted from the ALLHAT study, which evaluated 
the efﬁ  cacy of ACE inhibitors over other anti-hypertensives 
in prevention of cardiovascular events (ALLHAT 2002). 
The ALLHAT trial randomized 33357 patients with stage 
1 or 2 hypertension plus at least one risk factor for CHD 
to chlorthalidone, amlopdipine or lisinopril for a mean 
follow-up of 4.9 years. While there was no difference in the 
combined primary outcome (combined fatal CHD/non fatal 
MI) or secondary outcome of all cause mortality, it appears 
that the combined 6 year outcome of cardiovascular events 
was lower in the diuretic group. This has spurred tremendous 
debate about the utility of RAS blockade over traditional 
antihypertensive therapy. However, there are some important 
limitations that have been raised with this study. First of all, 
patients were treated with a multitude of “Step 2” drugs to 
achieve adequate BP control in addition to the study medica-
tion. The vascular effects of this additional therapy, which 
included reserpine, clonidine and atenolol, may have had 
some effect on the results. In addition, the lisinopril group 
had a systolic BP two mmHg higher than those on chlortha-
lidone, a potentially important difference given the large 
number of patients in the study. Furthermore, because of the 
study design, this was obviously a much lower risk popula-
tion with a much lower incidence of cardiovascular disease. 
Most striking, however, may be the dosing and type of ACE 
inhibition used in this study. Not only does lisinopril have a 
lower tissue-speciﬁ  c ACE inhibition than agents like ramipril, 
perindopril and trandolapril, by the end of the study period, 
only 73% of patients in the lisinopril group were actually 
receiving an ACE inhibitor and only 60% were at the maxi-
mum dose of 40 mg/day. Thus, while there may be credence 
to the hypothesis that ACE inhibition may only be beneﬁ  cial 
for those at higher cardiovascular risk, it must be noted that 
there are some limitations to these studies that may weaken 
any sweeping generalizations about superiority of alternative 
antihypertensive medications.
Another negative, albeit smaller, study that has brought 
into question the utility of ACE inhibitors in all patients 
with coronary atherosclerosis was the CAMELOT study 
(Nissen et al 2004). In this trial, 1997 normotensive patients 
with documented coronary disease by angiography were 
randomized to either amlodipine 10 mg, enalapril 20 mg 
or placebo for 24 months with a similar composite primary 
end point of cardiovascular event (cardiovascular death, 
non fatal MI, resuscitated cardiac arrest, coronary revascu-
larization, fatal or non fatal stroke, TIA or new diagnosis of 
peripheral vascular disease). Despite similar reductions in 
blood pressure in both groups, it was found that amlodipine, 
but not enalapril, signiﬁ  cantly reduced the primary outcome 
compared to placebo. In addition, in a subgroup analysis Vascular Health and Risk Management 2007:3(6) 942
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using intravascular ultrasound, they found that amlodipine 
halted progression of atherosclerosis while there was a trend 
towards progression of atherosclerosis in the enalapril group 
compared to placebo. The neutral effects of ACE inhibition 
in this study can be explained through similar arguments to 
those in previous studies. This was a lower risk population 
and younger population than other studies. Once again, the 
use of a lower tissue-speciﬁ  c ACE inhibitor brings into 
question whether these agents may be less efﬁ  cacious. In 
addition, there were a very high percentage of patients on 
statins (82%–83%), which was signiﬁ  cantly more than in any 
of the other ACE inhibitor studies. Another unique limitation 
to this study was the duration of therapy used, two years, as 
the full effect of ACE inhibitors has been hypothesized to 
take up to three years.
Another smaller study that failed to ﬁ  nd signiﬁ  cant 
effects of ACE inhibitors on atherosclerosis was the PART 
2 trial. In this study, 617 patients with coronary artery dis-
ease, peripheral vascular disease and carotid atherosclerosis 
were randomized to ramipril or placebo for four years with 
outcomes of carotid intima media thickness (CIMT) and 
left ventricular mass by echocardiography. While ramipril 
did produce a signiﬁ  cant reduction in left ventricular mass, 
there was no signiﬁ  cant difference in the carotid thickness 
progression between the two groups. However, this study was 
not powered to detect a difference in cardiovascular events 
(MacMahon et al 2000).
Despite a tremendous amount of heterogeneity between 
all of these studies, it should also be noted that there has 
been a meta-analysis of most of the pertinent trials with 
ACE inhibitors in patients with coronary atherosclerosis 
(HOPE, EUROPA, PEACE, QUIET, and PART-2 AND 
CAMELOT). From this meta-analysis, it was found that 
there was a favorable, modest beneﬁ  t of ACE inhibitors 
in patients with CAD and preserved ventricular function 
on combined cardiovascular outcome used in these studies 
(Al-Mallah et al 2006).
Thus, the most important conclusion to draw from all 
of these studies is that ACE inhibitors seem to have beneﬁ  -
cial effects in decreasing cardiovascular events in patients 
with high risk coronary atherosclerosis (as deﬁ  ned by the 
populations in HOPE and EUROPA). The beneﬁ  t in other 
populations is unclear, as is evident from the conﬂ  icting 
results in the other mentioned trials. These conﬂ  icting results 
could have a variety of explanations, including variations in 
population characteristics, degree of blood pressure lower-
ing, whether patients were on statins and/or had low LDL 
levels, use of tissue-speciﬁ  c ACE inhibitors, duration of the 
treatment and the dosage of ACE inhibitor. This heterogeneity 
has to be taken into account when analyzing these studies and 
concluding if ACE inhibitors should be used in patients with 
or at high risk of developing coronary atherosclerosis.
Clinical trials on angiotensin 
receptor blockers in stable CAD
In addition to blockade of the RAS system via ACE inhibi-
tion, direct blockade of Ang II receptors has proven to be ben-
eﬁ  cial in patients with systolic dysfunction and myocardial 
infarction (Pfeffer, McMurray et al 2003; Pfeffer, Swedberg 
et al 2003). Given that there is a plethora of experimental data 
on the beneﬁ  t of these agents in the atherosclerotic process, 
it would seem intuitive that ARBs could also have a poten-
tial role in this population. However, the clinical evidence 
for ARBs in stable coronary atherosclerosis is more limited 
than that for ACE inhibitors and has largely been conﬁ  ned 
to small clinical trials using surrogate markers.
Nonetheless, of the clinical trials that have addressed 
the efﬁ  cacy of ARBs, there has been promise for the utility 
of these agents in this population. In one study examining 
patients following percutaneous coronary intervention, 
patients treated with candesartan for 24 months had a signiﬁ  -
cant decrease in a composite cardiovascular endpoint (non 
fatal MI, cardiovascular death, and revascularization, with 
a secondary end point of hospitalization for cardiovascular 
causes) when compared to placebo (Kondo et al 2003). Inter-
estingly, this effect was seen despite no difference in mean 
blood pressure during the course of the trial between the 
two groups. However, several additional conclusions were 
drawn from this study. First, there was no effect of ARBs on 
CRP levels during the study period, a ﬁ  nding supported by 
previously smaller clinical trials (Andersen et al 2000; Prasad 
et al 2001; Tan et al 2002). Second, there was achievement 
of the primary outcome without a signiﬁ  cant change in blood 
pressure, once again conﬁ  rming that the clinical beneﬁ  t of 
these agents is likely independent of blood pressure effects. 
While it seems likely that the mechanism of this effect is 
related to the vasculoprotective effects of RAS blockade, 
this study did not deﬁ  nitively evaluate these issues.
The LIFE trial, another comparative trial evaluating the 
efﬁ  cacy of ARBs in hypertension, also sheds some insight 
into the clinical beneﬁ  t of these agents. This trial randomized 
9193 patients with normal ventricular function and hyperten-
sion to either atenolol (50 or 100 mg/day) or losartan (50 or 
100 mg/day) for a follow-up of four years (Dahlöf et al 2002). 
The primary end point was a similar composite end point of 
cardiovascular death, MI and stroke that has been used in Vascular Health and Risk Management 2007:3(6) 943
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other studies. While both groups had a similar reduction in 
blood pressure, there was a signiﬁ  cant decrease in the primary 
outcome in those patients treated with losartan. This clinical 
beneﬁ  t of ARBs seemed to be driven by the reduction in the 
incidence of stroke, rather than a lower incidence of myo-
cardial infarction, coronary revascularization and CV death. 
Once again, this study gives credence to the notion that there 
is clinical beneﬁ  t to ARBs in cardiovascular disease and it is 
independent of blood pressure control. At present, there is 
an ongoing study, the ONTARGET (ONgoing Telmisartan 
Alone and in combination with Ramipril Global Endpoint 
Trial) study. This investigation is nearing completion, and 
the results should be reported shortly. This study investigates 
the role of the angiotensin II receptor blocker telmisartan 
and the ACE inhibitor ramipril alone or in combination in 
the prevention of stroke, myocardial infarction and cardio-
vascular death. A parallel study, the TRANSCEND study, 
which stands for Telmisartan Randomised AssessmeNt Study 
in ACE-iNtolerant subjects with cardiovascular Disease, 
compares telmisartan against placebo in patients who are 
intolerant to ACE inhibitors and is scheduled to be reported 
at about the same time (Yusuf 2002).
In conclusion, ARBs decrease mortality and morbidity 
in patients with CHF and MI, likely with similar efﬁ  cacy to 
ACE inhibition. However, the clinical evidence in decreasing 
adverse cardiovascular outcomes in patients with coronary 
atherosclerosis remains limited. Hence, before judgments are 
made regarding their role in this population, we need both 
more clinical trials to assess their utility, in addition to better 
understanding of the mechanisms behind their efﬁ  cacy.
Renin inhibitors: A look into the future
The potential for renin inhibition as a target for blockade 
of the RAS has been considered for more than 30 years, as 
renin is the initial and rate limiting step in the RAS system 
(Skegg et al 1957). To date, elucidation and release of an 
effective direct renin inhibitor have failed for multiple 
reasons, including achieving effective potency, poor oral 
bioavailability and high cost. With the advent of new tech-
nology using x-ray crystallography and reconstruction of the 
structure of the active site, there has been creation of novel 
agents that may overcome these shortcomings (Fisher and 
Hollenberg 2005).
The rationale for direct renin inhibition is multifaceted. 
It is known that renin is the rate limiting step in the RAS 
(Nussberger et al 2002). Furthermore, plasma renin active 
concentration is the most sensitive marker of RAS activity, 
with a striking relationship between onset of diabetic 
micro vascular disease correlating well to elevated plasma 
concentrations of pro-renin (Franken et al 1990; Fisher 
and Hollenberg 2005). Renin inhibitors have a remarkable 
speciﬁ  city for its substrate, which will reduce the likeli-
hood of unwanted interactions and side effects. Addition-
ally, blockade at the beginning of the pathway will lead to 
decreased levels of Ang I, bradykinin, Ang II and aldosterone 
(Nussberger et al 2002). Theoretically, direct renin inhibi-
tion should also eliminate the potential for bradykinin and 
substance P related side effects, such as cough and angio-
edema, seen with ACE inhibition. In addition, while direct 
renin inhibitors will decrease levels of Ang II, most ARBs 
lead to increased levels of Ang II. While they block the AT1 
receptor and negative many of the ill effects of Ang II, there 
is a paucity of information about the long term effects of 
elevated Ang II levels on the AT2 receptors.
With this potential beneﬁ  t, a direct renin inhibitor, aliskiren 
(SPP100) was recently approved by the Food and Drug 
Administration (FDA) for treatment of hypertension. In a 
double-blinded, crossover study, eighteen healthy volunteers 
were placed on a 100 mmol Na diet for a period of 6 weeks, 
then randomized to either placebo, enalapril (20 mg/day) or 
two dosing regimens of aliskiren. The results of this study 
have been encouraging, as the medication seems to be well-
tolerated with similar adverse events in all groups. Aliskiren 
was found to inhibit RAS activity in a dose dependent 
manner, with a maximum reduction in Ang II levels by the 
ﬁ  rst hour after administration of the dose and suppression 
up to six hours. This was in contrast to enalapril, which 
decreased its levels only after six hours. In addition to Ang II, 
plasma renin activity and Ang I were also decreased, while 
enalapril produced the expected increase in these levels by 
up to ﬁ  fteen fold. Both drugs result in enhanced levels of 
renin. Thus, from a physiologic perspective, aliskiren seems 
a promising drug which shows effective blockade of the RAS 
(Nussberger et al 2002).
Furthermore, at least one study looking at patients 
with hypertension has shown that this agent effectively 
decreases blood pressure. In this safety and efﬁ  cacy study, 
226 hypertensive patients were randomized to receive 
variable doses of aliskiren or losartan (100 mg/day) for 4 
weeks. There was a dose dependent reduction in daytime 
ambulatory systolic pressure of 11 mmHg with maximum 
dose of aliskerin (300 mg/day), which was comparable to 
the dose of losartan used in the study. Rates of side effects 
and adverse events were not signiﬁ  cantly different between 
treatment groups (Stanton et al 2003). A more recent study 
compared the effects of aliskiren to valsartan, both separately Vascular Health and Risk Management 2007:3(6) 944
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and in combination. While they were similar in tolerability 
and reduction in blood pressure, it is interesting to note that the 
combination was also found to be tolerable (Pool et al 2007).
Thus, direct renin inhibitors such as aliskerin hold further 
promise in elucidating the importance of the RAS in coronary 
atherosclerosis. Obviously, their efﬁ  cacy is far from proven, 
but this drug opens the door for many more studies to answer 
a multitude of questions. Speciﬁ  cally, will this drug be use-
ful in combination with other RAS-blocking agents? Will 
this drug more effectively reduce levels of the important 
pathophysiologic mediators of the RAS? Do these agents 
have a role beyond anti-hypertensives, in the prevention and 
treatment of diabetic micro vascular disease, atherosclerosis 
and systolic dysfunction?
Conclusion
The evidence for the renin angiotensin system as an important 
mediator of many pathologic cardiovascular processes has 
become overwhelming. However, while several classes of 
agents that block the RAS have shown clinical promise in pre-
venting important cardiovascular outcomes, the exact mecha-
nisms of these effects have not been fully realized. There does 
appear to be important effects on insulin resistance and lipid 
metabolism, two critical risk factors for cardiovascular dis-
ease. In addition, there are also important effects of the RAS on 
all steps in the atherosclerotic process, including endothelial 
dysfunction, inﬂ  ammation, thrombosis and plaque stabiliza-
tion, which we have not discussed in this review. While there 
have been multiple large-scale trials on the efﬁ  cacy of ACE 
inhibitors in patients with stable coronary atherosclerosis, 
their beneﬁ  t in this population remains unclear. The data for 
ARBs is even more limited, but certainly suggests promis-
ing beneﬁ  t. We now also have direct renin inhibitors, which 
promise to add even further insights into our understanding of 
the RAS. Whether these agents that inhibit the RAS are useful 
in all patients with atherosclerosis remains to be seen and will 
certainly be the topic of future clinical studies.
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